{"nctId":"NCT03473223","briefTitle":"Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome","startDateStruct":{"date":"2018-03-21","type":"ACTUAL"},"conditions":["Acute Coronary Syndrome"],"count":18226,"armGroups":[{"label":"CSL112","type":"EXPERIMENTAL","interventionNames":["Biological: Apolipoprotein A-I [human] (apoA-I)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Apolipoprotein A-I [human] (apoA-I)","otherNames":["CSL112"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female least 18 years of age\n* Evidence of myocardial necrosis, consistent with type I (spontaneous) MI\n* No suspicion of acute kidney injury\n* Evidence of multivessel coronary artery disease\n* Presence of established cardiovascular risk factor(s):\n\n  1. Diabetes mellitus on pharmacotherapy OR\n  2. 2 or more of the following: age â‰¥ 65 years, prior history of MI, peripheral arterial disease\n\nExclusion Criteria:\n\n* Ongoing hemodynamic instability\n* Evidence of hepatobiliary disease\n* Evidence of severe chronic kidney disease\n* Plan to undergo scheduled coronary artery bypass graft surgery as treatment for the index MI\n* Known history of allergies, hypersensitivity, or deficiencies to soy bean, peanut or albumin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke)","description":"MACE (Major adverse cardiovascular event\\[s\\])(CV \\[cardiovascular\\] death, MI \\[Myocardial Infarction\\], or stroke).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"439","spread":null},{"groupId":"OG001","value":"472","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Hospitalizations for Coronary, Cerebral, and Peripheral Ischemia","description":"The total number of hospitalizations and individual hospitalizations due to coronary, cerebral, and peripheral ischemia were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"433","spread":null},{"groupId":"OG001","value":"442","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"367","spread":null},{"groupId":"OG001","value":"376","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With First Occurrence of CV Death, MI, or Stroke","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"622","spread":null},{"groupId":"OG001","value":"683","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With First Occurrence of CV Death, MI, or Stroke","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"885","spread":null},{"groupId":"OG001","value":"944","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Occurrence of CV Death","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"128","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With First Occurrence of MI","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"312","spread":null},{"groupId":"OG001","value":"342","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With First Occurrence of Stroke","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With First Occurrence of CV Death, Type 1 MI or Stroke","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"272","spread":null},{"groupId":"OG001","value":"308","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"400","spread":null},{"groupId":"OG001","value":"444","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"594","spread":null},{"groupId":"OG001","value":"639","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Occurrence of All-cause Death","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341","spread":null},{"groupId":"OG001","value":"345","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"An AE was defined as any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3938","spread":null},{"groupId":"OG001","value":"3927","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"An AE was defined as any unfavorable and unintended sign (including an abnormal, clinically significant laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.7","spread":null},{"groupId":"OG001","value":"43.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-related Adverse Events","description":"Treatment-related AEs were AEs considered by the Investigator to have a causal relationship to the investigational product.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null},{"groupId":"OG001","value":"304","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment-related Adverse Events","description":"Treatment-related AEs were AEs considered by the Investigator to have a causal relationship to the investigational product. As per the study statistical analysis plan (SAP), descriptive percentages were displayed to one decimal place, hence the percentage values were rounded off and presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is a medically significant event.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1514","spread":null},{"groupId":"OG001","value":"1557","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SAEs","description":"SAE was defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is a medically significant event. As per the study SAP, descriptive percentages were displayed to one decimal place, hence the percentage values were rounded off and presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Shift From Baseline to Worst Post-treatment Value in Clinical Laboratory Assessments","description":"Clinical laboratory assessments included assessment of Hematology (hemoglobin, hematocrit, leukocytes and platelets) and Biochemistry (alkaline phosphatase \\[ALP\\], alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], bilirubin, direct bilirubin, indirect bilirubin and estimated glomerular filtration rate \\[eGFR\\]). The number of participants with a shift from the Baseline value to the worst post-treatment value (low, normal, or high) was reported. The worst criterion for the parameters is as follows: hematocrit - low, hemoglobin - low, leukocytes - high, platelets - low, ALT - high, ALP - high, AST - high, bilirubin - high, direct bilirubin - high, indirect bilirubin - high, eGFR - severe impairment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"393","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"457","spread":null},{"groupId":"OG001","value":"447","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"267","spread":null},{"groupId":"OG001","value":"271","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"114","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"658","spread":null},{"groupId":"OG001","value":"612","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"307","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Shift From Baseline to Worst Post-treatment Value in Clinical Laboratory Assessments","description":"Clinical laboratory assessments included assessment of Hematology (hemoglobin, hematocrit, leukocytes and platelets) and Biochemistry (ALP, ALT, AST, bilirubin, direct bilirubin, indirect bilirubin and eGFR). Percentage of participants with a shift from the Baseline value to the worst post-treatment value (low, normal, or high) was reported. The worst criterion for the parameters is as follows: hematocrit - low, hemoglobin - low, leukocytes - high, platelets - low, ALT - high, ALP - high, AST - high, bilirubin - high, direct bilirubin - high, indirect bilirubin - high, eGFR - severe impairment. As per the study SAP, descriptive percentages were displayed to one decimal place, hence the percentage values were rounded off and presented.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"3.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null},{"groupId":"OG001","value":"3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hematology Parameters","description":"Hematology parameters included Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.004","spread":"0.0455"},{"groupId":"OG001","value":"0.005","spread":"0.0462"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.045","spread":"0.1766"},{"groupId":"OG001","value":"0.047","spread":"0.1727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.024","spread":"2.2905"},{"groupId":"OG001","value":"-0.969","spread":"2.2683"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.084","spread":"0.5534"},{"groupId":"OG001","value":"0.080","spread":"0.5409"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.089","spread":"0.1886"},{"groupId":"OG001","value":"-0.087","spread":"0.1961"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.068","spread":"2.0892"},{"groupId":"OG001","value":"-1.011","spread":"2.0343"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"56.09"},{"groupId":"OG001","value":"-1.4","spread":"55.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hematology Parameter: Hematocrit","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.003","spread":"0.0382"},{"groupId":"OG001","value":"-0.004","spread":"0.0381"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hematology Parameter: Hemoglobin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"11.96"},{"groupId":"OG001","value":"-1.3","spread":"12.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hepatic Parameters","description":"Hepatic parameters included ALT, ALP and AST.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"25.52"},{"groupId":"OG001","value":"-6.5","spread":"28.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"26.13"},{"groupId":"OG001","value":"4.5","spread":"24.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.2","spread":"41.90"},{"groupId":"OG001","value":"-20.7","spread":"61.63"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hepatic Parameter: Bilirubin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"4.71"},{"groupId":"OG001","value":"-1.9","spread":"5.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.32"},{"groupId":"OG001","value":"-0.3","spread":"1.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"3.85"},{"groupId":"OG001","value":"-1.4","spread":"3.90"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Renal Parameter: Serum Creatinine","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"24.39"},{"groupId":"OG001","value":"2.1","spread":"21.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Renal Parameter: eGFR","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"11.87"},{"groupId":"OG001","value":"-1.2","spread":"12.15"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Renal Parameter: Blood Urea Nitrogen","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"2.76"},{"groupId":"OG001","value":"0.0","spread":"2.67"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1514,"n":9010},"commonTop":[]}}}